Kazakhstan vs Suriname: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Kazakhstan
0.2%
in 2024
Suriname
0.2%
in 2024
Kazakhstan rank
98th
Suriname rank
98th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Kazakhstan
- Suriname
How they compare
Kazakhstan currently reports 0.2% against 0.2% in Suriname, a difference of 0.0%.
Across all 10 years both countries report, Suriname has been ahead every year.
Kazakhstan ranks 98th and Suriname ranks 98th of 246 countries.
Head to head by decade
| Decade | Kazakhstan | Suriname | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.2% | 0.2% | 0.0% | — |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Kazakhstan or Suriname?
- Kazakhstan, at 0.2% against 0.2% in Suriname as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Kazakhstan and Suriname?
- 0.0%, with Kazakhstan ahead.
- How many years of comparable data are there for Kazakhstan and Suriname?
- 10 years are reported by both, from 2015 to 2024.
- How do Kazakhstan and Suriname rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Kazakhstan ranks 98th and Suriname ranks 98th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.